Atlas Trials

First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients

Clinical trial NCT06121401 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06121401
Sponsor
Mario Negri Institute for Pharmacological Research
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 4
Study type
INTERVENTIONAL
Carcinoma, Ovarian Epithelial
Start date
2023-09-15
Primary completion
2027-03-15
Enrollment
190

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.